Close Menu

NEW YORK (GenomeWeb) – Biocept said today that it has made a preferred provider agreement with Teneovita Medical under which the Vancouver-based provider will market and distribute Biocept's Target Selector liquid biopsy testing services to hospitals, individual oncology practices, and other cancer centers in Canada.

Additional terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.